Jessica E. Ericson

Jessica E. Ericson

Auto-generated profile, based on publicly available information

Jessica E. Ericson

Penn State College of Medicine, Hershey, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
JEJessica E. Ericson
Jessica E. Ericson
VPVictor O. Popoola
Victor O. Popoola
PSP. Brian Smith
P. Brian Smith
DBDaniel K. Benjamin
Daniel K. Benjamin
VFVance G. Fowler
Vance G. Fowler
AMAaron M. Milstone
Aaron M. Milstone
Staphylococcus aureus is a frequent cause of infection in hospitalized infants.1 Infections due to S aureus are associated with increased mortality,2 morbidity,3 and length of hospital stay.4Staphylococcus aureus is the second most frequent cause of late-onset sepsis in very low-birth-weight (VLBW) infants less than 1500 g1 and is resistant to methicillin sodium in 8% to 28% of cases.5-7

1 March 2015 in Clinics in Perinatology
Verified
Journal Article
Closed access
JEJessica E. Ericson
Jessica E. Ericson
MLMatthew M. Laughon
Matthew M. Laughon

13 June 2016 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JEJessica E. Ericson
Jessica E. Ericson
DKDavid A. Kaufman
David A. Kaufman
SKStephen D. Kicklighter
Stephen D. Kicklighter
JBJatinder Bhatia
Jatinder Bhatia
DCDaniela Testoni Costa-Nobre
Daniela Testoni Costa-Nobre
DBDaniel K. Benjamin
Daniel K. Benjamin
Background. Invasive candidiasis (IC) is an important cause of sepsis in premature infants and is associated with a high risk of death and neurodevelopmental impairment. Prevention of IC has become a major focus in very low birth weight infants, with fluconazole increasingly used as prophylaxis. Methods. We identified all randomized, placebo-controlled trials evaluating fluconazole prophylaxis in premature infants conducted in the United States. We obtained patient-level data from the study investigators and performed an aggregated analysis. The occurrence of each endpoint in infants who received prophylaxis with fluconazole vs placebo was compared. Endpoints evaluated were IC or death, IC, death, Candida colonization, and fluconazole resistance among tested isolates. Safety endpoints evaluated included clinical and laboratory parameters. Results. Fluconazole prophylaxis reduced the odds of IC or death, IC, and Candida colonization during the drug exposure period compared with infants given placebo: odds ratios of 0.48 (95% confidence interval [CI], .30–.78), 0.20 (95% CI, .08–.51), and 0.28 (95% CI, .18–.41), respectively. The incidence of clinical and laboratory adverse events was similar for infants who received fluconazole compared with placebo. There was no statistically significant difference in the proportion of tested isolates that were resistant to fluconazole between the fluconazole and placebo groups. Conclusions. Fluconazole prophylaxis is effective and safe in reducing IC and Candida colonization in premature infants, and has no impact on resistance.

30 September 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
JPJoseph N. Paulson
Joseph N. Paulson
BWBrent L. Williams
Brent L. Williams
CHChristine Hehnly
Christine Hehnly
NMNischay Mishra
Nischay Mishra
SSShamim A. Sinnar
Shamim A. Sinnar
SSSteven Schiff
Steven Schiff
A new strain of the bacteriumPaenibacilluscontributes to postinfectious hydrocephalus in Ugandan infants.

1 April 2015 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
JEJessica E. Ericson
Jessica E. Ericson
JTJoshua Thaden
Joshua Thaden
HCHeather R. Cross
Heather R. Cross
RCReese H. Clark
Reese H. Clark
VFVance G. Fowler
Vance G. Fowler
PSP. Brian Smith
P. Brian Smith
Background: Coagulase-negative Staphylococcus (CoNS) is the most common cause of bloodstream infections (BSI) in hospitalized infants. CoNS BSI is most reliably treated with vancomycin; however, concerns about side effects and promoting resistance often delay empirical vancomycin therapy until culture results become available. Methods: All infants with CoNS BSI discharged from 348 neonatal intensive care units managed by the Pediatrix Medical Group from 1997 to 2012 were identified. Empirical vancomycin therapy was defined as vancomycin exposure on the day of the first positive blood culture. Delayed vancomycin therapy was defined as vancomycin exposure 1–3 days after the first positive blood culture. We used multivariable logistic regression with random effects for site to evaluate the association between the use of empirical vancomycin therapy versus delayed vancomycin therapy and 30-day mortality, controlling for gestational age, small-for-gestational age status, postnatal age on the day of the first positive culture, oxygen requirement, ventilator support and inotropic support on the day the first positive culture was obtained. Results: A total of 4364 infants with CoNS BSI were identified; 2848 (65%) were treated with empirical vancomycin. The median postnatal age at first positive culture was 14 days (interquartile range: 9, 21). Unadjusted 30-day mortality was similar for infants treated with empirical vancomycin and infants treated with delayed vancomycin therapy [166/2848 (6%) vs. 69/1516 (4%); P = 0.08]. There was no significant difference in 30-day mortality on multivariable analysis [odds ratio: 1.14 (0.84, 1.56)]. The median duration of bacteremia was 1 day longer for infants with delayed vancomycin therapy [4 days (interquartile range: 2, 6) vs. 3 days (2, 5); P < 0.0001]. Conclusions: The median duration of bacteremia was 1 day longer in infants with CoNS BSI who received delayed vancomycin therapy. Despite this finding, empirical vancomycin therapy for CoNS BSI was not associated with improved mortality.

1 September 2015 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
SBStephen P. Bergin
Stephen P. Bergin
JTJoshua T. Thaden
Joshua T. Thaden
JEJessica E. Ericson
Jessica E. Ericson
HCHeather Cross
Heather Cross
JMJulia Messina
Julia Messina
PSP. Brian Smith
P. Brian Smith
Background: Escherichia coli is a common cause of bloodstream infections (BSIs) in infants and is associated with high mortality and morbidity among survivors. The clinical significance of antibiotic resistance and timing of appropriate antimicrobial therapy in this population is poorly understood. Methods: We identified all infants with E. coli BSIs discharged from 77 neonatal intensive care units managed by the Pediatrix Medical Group in 2012. We used multivariable logistic regression to evaluate the association between 30-day mortality and ampicillin-resistant E. coli BSI, as well as the number of active empiric antimicrobial agents administered, controlling for gestational age, small-for-gestational age status, early-onset versus late-onset BSI, oxygen requirement, ventilator support and inotropic support on the day of the first positive blood culture. Results: We identified 258 episodes of E. coli BSI, including 123 (48%) ampicillin-resistant isolates. Unadjusted 30-day mortality did not significantly differ between infants with ampicillin-resistant versus ampicillin-susceptible E. coli BSI [11 of 123 (9%) vs. 7 of 135 (5%); P = 0.33; adjusted odds ratio = 1.37 (95% confidence interval: 0.39, 4.77)]. Among ampicillin-resistant E. coli BSIs, 30-day mortality was not significantly lower for infants treated with at least one empiric antimicrobial active against ampicillin-resistant E. coli versus infants receiving no active empiric agent [adjusted odds ratio = 1.50 (0.07, 33.6)]. Conclusions: In this population of infants with E. coli BSI, ampicillin resistance was not associated with significantly increased mortality. Among the subset of infants with ampicillin-resistant E. coli, appropriate empirical antibiotic therapy was not associated with lower mortality.